Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.
Centogene and Lifera team up for genetic testing service in Saudi Arabia – Pharmaceutical Technology
As part of Saudi Vision 2030, the country’s health sector is seeing a swathe of transformation and investments. Image credit: Shutterstock/hyotographics Multiomic testing is advancing
June 28, 2023